Lilly(US:LLY) Zhi Tong Cai Jing·2026-01-13 07:04Core Viewpoint - Eli Lilly's new weight loss drug orforglipron is expected to be approved for market launch this quarter, with the company prepared to meet market demand [1] Group 1: Drug Approval and Market Readiness - Orforglipron received priority review status from the FDA in November last year, significantly shortening the review period from the standard 10-12 months to just 1-2 months [1] - The company submitted the formal application for the drug's market approval to the FDA in December [1] - Eli Lilly plans to initiate the launch process simultaneously in multiple countries globally as soon as approval is granted [1] Group 2: Investment and Pricing Strategy - The company has invested hundreds of millions of dollars in building production facilities for orforglipron [1] - The initial monthly price for self-paying patients is set at $149, with higher dosage options increasing the monthly cost to $399 [1] Group 3: Competitive Landscape - Upon approval, orforglipron will face competition from Novo Nordisk's oral weight loss drug Wegovy, which was launched in early January at a similar initial self-pay price [1]